)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
BioVie
BioVie (BIVI) investor relations material
BioVie Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary14 Aug, 2026
Company overview and business model
Focuses on developing innovative drug therapies for neurological, neurodegenerative disorders, and advanced liver disease.
Lead asset bezisterim (NE3107) targets inflammation-driven insulin resistance, with programs in Alzheimer's, Parkinson's, and long COVID.
Liver program BIV201 (terlipressin) targets ascites in cirrhosis, with FDA Fast Track and Orphan Drug status.
Financial performance and metrics
As of June 30, 2026, cash and cash equivalents were $10.3M (actual), $14.3M (as adjusted), and $33.0M (as further adjusted for the offering).
Accumulated deficit stands at $374.3M, with total stockholders' equity at $34.3M (as further adjusted).
Net tangible book value per share post-offering is estimated at $1.39, with immediate dilution of $0.17 per share to new investors.
Use of proceeds and capital allocation
Estimated net proceeds of $22.7M (assuming full sale at $1.56 per share), with no minimum offering amount.
Proceeds intended for working capital, general corporate purposes, capital expenditures, R&D, and potential acquisitions.
Management has broad discretion over allocation of funds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from BioVie
- Net loss rose to $22.1M in FY2026; ongoing clinical trials and funding needs raise going concern doubts.BIVI
Q4 2026 - Bezisterim improved motor, non-motor symptoms, and biomarkers, supporting Phase III advancement.BIVIStudy result
- Biotech seeks $70M in best efforts IPO to fund R&D amid ongoing losses and litigation risks.BIVIRegistration filing
- Biotech seeks up to $70M via share and warrant offering to fund R&D, facing high risk and dilution.BIVIRegistration filing
- Biotech seeks capital for late-stage neuro and liver drug programs amid ongoing losses and legal risks.BIVIRegistration filing
- Bezisterim targets neuroinflammation in early Parkinson's with a novel, patient-friendly trial design.BIVIStatus Update
- All directors re-elected and key proposals, including auditor and equity plan, passed with strong support.BIVIAGM 2024
- Biotech seeks to raise up to $300M for neuro and liver disease R&D via flexible securities offering.BIVIRegistration filing
- Imminent clinical data for Parkinson's and Long COVID could unlock major market opportunities.BIVIInvestor update
Next BioVie earnings date
Q1 20279 Nov, 2026
BioVie
Next BioVie earnings date
Q1 20279 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage